表紙
市場調査レポート

末梢性T細胞リンパ腫 (PTCL):パイプライン製品の分析

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 264096
出版日 ページ情報 英文 226 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
末梢性T細胞リンパ腫 (PTCL):パイプライン製品の分析 Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 226 Pages
概要

末梢性T細胞リンパ腫 (PTCL) は、Tリンパ球と呼ばれる白血球 (T細胞) から発生する、希少で侵攻性の (急成長する) 癌です。T細胞は免疫系の重要な要素で、体が感染症と闘うのを助けます。T細胞が急速に成長し、瀕死で抵抗し始めると、体内に蓄積されます。症状として、倦怠感、首・脇の下・鼠径部の痛みのない腫れ、寝汗、発疹などが見られます。

当レポートでは、末梢性T細胞リンパ腫 (PTCL) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

末梢性T細胞リンパ腫 (PTCL) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

末梢性T細胞リンパ腫 (PTCL):企業で開発中の治療薬

末梢性T細胞リンパ腫 (PTCL):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

末梢性T細胞リンパ腫 (PTCL):企業で開発中の製品

末梢性T細胞リンパ腫 (PTCL) の治療薬開発に従事している企業

  • AB Science SA
  • Affimed Therapeutics AG
  • Bayer AG
  • Celgene Corporation
  • CerRx, Inc.
  • Chipscreen Biosciences Ltd
  • エーザイ
  • Incyte Corporation
  • Johnson & Johnson
  • Karyopharm Therapeutics, Inc.
  • 協和発酵キリン
  • Mundipharma International Ltd
  • Onxeo SA
  • Pfizer Inc.
  • Sanofi
  • ソレイジア・ファーマ
  • Spectrum Pharmaceuticals, Inc.
  • TG Therapeutics, Inc.

末梢性T細胞リンパ腫 (PTCL):治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AFM-13
  • alemtuzumab
  • belinostat
  • copanlisib hydrochloride
  • CS-055
  • darinaparsin
  • denileukin diftitox
  • fenretinide
  • forodesine hydrochloride
  • lenalidomide
  • masitinib
  • mogamulizumab
  • pralatrexate
  • romidepsin
  • ruxolitinib phosphate
  • selinexor
  • SH-7129
  • temsirolimus
  • TGR-1202
  • tipifarnib

末梢性T細胞リンパ腫 (PTCL):最近のパイプライン動向

末梢性T細胞リンパ腫 (PTCL):休止中のプロジェクト

末梢性T細胞リンパ腫 (PTCL):開発が中止された製品

末梢性T細胞リンパ腫 (PTCL):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7729IDB

Summary

Global Markets Direct's, 'Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016', provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
  • The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects
  • The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peripheral T-Cell Lymphomas (PTCL) Overview
  • Therapeutics Development
    • Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview
  • Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies
  • Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development
    • AB Science SA
    • Affimed Therapeutics AG
    • Bayer AG
    • Celgene Corporation
    • CerRx, Inc.
    • Chipscreen Biosciences Ltd
    • Eisai Co., Ltd.
    • Incyte Corporation
    • Johnson & Johnson
    • Karyopharm Therapeutics, Inc.
    • Mundipharma International Ltd
    • Ono Pharmaceutical Co., Ltd.
    • Onxeo SA
    • Pfizer Inc.
    • Rhizen Pharmaceuticals S.A.
    • Seattle Genetics, Inc.
    • Solasia Pharma K.K.
    • Spectrum Pharmaceuticals, Inc.
    • TG Therapeutics, Inc.
  • Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AFM-13 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • belinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brentuximab vedotin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • copanlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CS-055 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darinaparsin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • denileukin diftitox - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fenretinide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • forodesine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mitoxantrone hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NL-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pralatrexate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • romidepsin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RP-6530 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ruxolitinib phosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SH-7129 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • temsirolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TGR-1202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tipifarnib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Peripheral T-Cell Lymphomas (PTCL) - Recent Pipeline Updates
  • Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects
  • Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products
  • Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
      • Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015
      • Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP
      • Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma
      • Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma
      • Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology
      • May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3
      • Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
      • Dec 09, 2014: Combination of ISTODAX (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma
      • Dec 05, 2014: Spectrum Pharmaceuticals Highlights Abstracts on Beleodaq (belinostat) at the 56th Annual Meeting of the ASH in San Francisco
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer
\n

List of Tables

  • Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed Therapeutics AG, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Seattle Genetics, Inc., H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by TG Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Recent Pipeline Updates, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H1 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top